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Mobile genetic Elements (MEs) are segments of DNA which can copy themselves and other
transcribed sequences through the process of retrotransposition (RT). In humans several
disorders have been attributed to RT, but the role of RT in severe developmental disorders
(DD) has not yet been explored. Here we identify RT-derived events in 9738 exome
sequenced trios with DD-affected probands. We ascertain 9 de novo MEs, 4 of which are
likely causative of the patient’s symptoms (0.04%), as well as 2 de novo gene retro-
duplications. Beyond identifying likely diagnostic RT events, we estimate genome-wide
germline ME mutation rate and selective constraint and demonstrate that coding RT events
have signatures of purifying selection equivalent to those of truncating mutations. Overall,
our analysis represents a comprehensive interrogation of the impact of retrotransposition on
protein coding genes and a framework for future evolutionary and disease studies.
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In humans, three classes of mobile genetic elements (MEs)—Alu, long interspersed nuclear element 1 (L1), and SINE-VNTR-Alu (SVA)—are still active and can generate new
copies, known as mobile element insertions (MEIs), throughout
their host genome1. The L1 replicative machinery can also facil-
itate the duplication of non-ME transcripts, typically protein-
coding genes, through the mechanism of retroduplication to
generate processed pseudogenes (PPGs)2. Combined, these two
processes constitute retrotransposition (RT) in the human gen-
ome, with new (de novo) MEI variants previously estimated to
occur in every 1 out of 18.4–26.0 births3. On a population level,
each individual human genome harbors ~1200 polymorphic
variants, with the smallest ME, Alu, generally contributing 75% of
total RT polymorphisms4–6.
To date, roughly 130 pathogenic variants caused by RT activity
have been documented7; however, the majority of these deleter-
ious events have been discovered in isolated cases. Neither MEIs
nor PPGs are canalyzed as part of routine clinical sequencing, and
thus represent a largely unassessed category of genetic variation
in many disorders. Furthermore, of the clinically relevant RT-
attributable cases thus identified, few (~14/123; 11.4%) are caused
by new mutational events and are instead typically attributable to
rare inherited polymorphisms7. In addition, of the large disease-
focused whole-genome sequencing (WGS) projects which have
ascertained MEIs, all have focused on autism8–10 and have failed
to identify likely causative RT-derived variants. In fact, in the
largest and most recent WGS study investigating the role of large
structural variants in the genetic architecture of autism, the
authors failed to identify a single de novo MEI in a coding exon,
deleterious or otherwise, in 829 families9. This finding is likely a
result of several factors, predominant among them the low fre-
quency of cases attributable to gene disruption by MEIs in aut-
ism10, due in part to a low ME mutation rate3 and lack of a
sufficiently large sample size8,9,11. As such, it is not precisely
known at what rate de novo ME variants are generated in the
human genome, the functional consequences of such variants, the
role that they play in the etiology of rare disease, and if routine
clinical sequencing should assess patient genomes for deleterious
RT events.
Herein, we analyze the whole-exome sequencing (WES) data
produced by the Deciphering Developmental Disorders (DDD)
study to systematically assess the role of RT in severe devel-
opmental disorders (DDs). The DDD data have already been
investigated for pathogenic single-nucleotide variants (SNVs),
small insertions and deletions (InDels), large copy number
variants (CNVs), and other classes of variation12–18. Approxi-
mately, 24% of DDD cases harbor a pathogenic de novo
mutation in a gene known to be associated with developmental
disorders12. The DDD cohort should thus be relatively enriched
for highly penetrant de novo RT events in comparison
with recent studies on autism8,9. With a cohort of 9738 trios
(n= 28,132 individuals) whole-exome sequenced, the DDD
study presents a powerful opportunity to identify, and ascertain
the role in DD of, pathogenic de novo RT events that impact
coding sequences.
Results
Generation of a genome-wide data set of RT variants. To assess
9738 DDD study trios for RT events, we utilized two separate
computational approaches to identify both MEIs and PPGs. First,
we used the mobile element locator tool (MELT)5 to identify Alu,
L1, and SVA variants located within the WES bait regions (see the
Methods section). The second is a new bespoke tool developed to
identify PPGs from the WES data (Methods, Supplementary
Fig. 1). Due to cross-hybridization between a PPG and the exome
baits targeting the donor gene, we anticipated that we should be
able to detect PPGs genome wide, not just the subset that insert
within the WES bait regions. Our PPG detection tool ascertained
putative PPGs by identifying multiple discordant read pairs
mapping to different exons of the same transcript, before then
typing all individuals for the presence/absence of the PPG using
discordant read pairs and split reads. The tool was optimized by
comparing against previously described PPG polymorphisms in
the 1000 genomes project (1KGP; see below).
As our study is the first to discover MEIs directly from WES on
a large scale with MELT, we first utilized matched sample WGS
data to determine if MELT could ascertain MEI variants reliably
from the WES data. We compared MEI variants identified by
MELT within the DDD WES data to both WGS data generated
for 90 overlapping DDD individuals and population MEI data
previously generated from the 1000 Genomes Project Phase 3
(1KPG)4–6 WGS data. The latter comparison was to ensure that
the number of exonic MEIs identified within DDD WES data was
concordant with expectations at the individual and population
level. When comparing our WES genotypes to WGS in the same
individuals, we had a genotype concordance rate of 94.46%
(93.93% Alu, 97.29% L1, 98.25% SVA) among calls with at least
10× coverage in our WES data. In total, we were able to re-
identify 1450 (1289 Alu, 160 L1, 1 SVA) MEI genotypes, or 84.5%
of all heterozygous or homozygous genotypes identifiable with
WGS in WES bait regions (Supplementary Table 1). Based on
these findings, we were confident that MELT was appropriately
calibrated to ascertain MEIs in WES data.
We identified 1129 MEI variants and 576 polymorphic PPGs,
with each individual’s exome containing on average 33.0 ± 5.0 (SD)
variants (Table 1). All MEIs were genotyped across all individuals to
form a comprehensive catalogue of RT-derived variation within and
adjacent to (±50 bp) sequences targeted in the WES assay
(Methods), including coding exons and targeted noncoding
elements (Table 1; Fig. 1). The average time to assess a single
family for RT-derived events was ~15min, and the rate of false
findings was low (1 incorrect candidate de novo variant per every
295 patients; either a false-positive variant [1 per 649] or false-
negative genotype [1 per 541] in at least one parent). We
investigated whether false-negative parental genotypes could be
Table 1 RT variant discovery in the DDD study
Total sites cohort-wide Mean sites per unaffected parent Total de novo sites
Alu 917 23.6 ± 4.2 7
LINE-1 167 2.8 ± 1.5 2
SVA 45 0.2 ± 0.5 0
Total - MEI 1129 26.6 ± 4.7 9
Processed pseudogenes (PPGs) 576 6.6 ± 1.7 2
Total – MEI+ PPG 1705 33.0 ± 5.0 11
Quantification of the four different classes of retrotransposons discovered as part of this study. Rows in italic indicate totals across the classes listed above
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mosaic. Using long-PCR coupled to long-read sequencing (see
methods), we were able to phase seven of our false-negative Alu
variants to nearby SNVs. With our approach, we determined that
one was part of a complex event of unknown mosaicism (FCGBP:
c.4743_4744insAlu(1_110)), and six were constitutive in both
parent and proband (Supplementary Fig. 2; Supplementary Data 2).
As expected, the total number of variants per individual for
each RT class (Fig. 1a–d) as well as combined number of RT
events (Fig. 1e) approximated a Poisson distribution (see the
Methods section; Supplementary Fig. 3). The vast majority of
variants are rare (allele frequency < 1 × 10–4; Fig. 1f), with > 65%
of Alu and L1 variants identified in fewer than four unrelated
individuals. SVA and PPGs appear to be moderately under
ascertained compared with Alu and L1 at lower AFs, with > 50%
of variants identified in the lowest AF bin and length estimates for
the three MEI classes largely fit the findings of previous studies
(Fig. 1g)4,5.
We next sought to ensure that our total number of ascertained
RT variants, both on a population and individual basis, accorded
with previously published WGS data4,5. On a population level,
WES did not appreciably limit our overall sensitivity compared
with the WGS sampled data. When we compared a downsampled
version of our call set to the 1KGP, our total number of Alu and
SVA variants fell within the expected distribution, while L1 was
close to expectation (Supplementary Fig. 4).
To assess the quality of the PPG call set, we compared PPG allele
counts (i.e., total number of individuals with a retroduplication of a
given gene) to a recent assessment of PPGs in samples sequenced as
part of the 1KGP6. Generally, PPGs identified in both data sets
shared similar relative allele counts (r2= 0.64) and variants
identified in this study, but missing from Zhang et al.6 are typically
rare (Supplementary Fig. 5). To further validate our approach and
ensure that the identified PPG donor genes fit with previously
identified patterns of germline PPG formation2,19, we assessed each
donor gene for both functional annotation and expression across 30
tissue types analyzed by the GTEx consortium20. The major
functional cluster (DAVID21 enrichment score 8.82) belonged to
genes involved in the ribosomal and translational machinery,
consistent with previous findings involving fixed PPGs in the
human genome2. Our expression analysis likewise confirmed
previous findings19, and shows that donor genes that give rise to
PPGs are more highly expressed in a large number of tissues
compared with non-retroposed genes (Wilcoxon rank sum p < 1 ×
10–3 for all tissues; Supplementary Fig. 6). In addition, while it could
be assumed that increased germ-line expression of a gene may play a
role in increased probability of PPG generation, when we compared
PPG donor gene expression in the testis and ovary to that in other
tissues, the majority of tissues (19/28, identical tissues for ovary and
testis) showed statistically identical patterns of donor gene
expression (Wilcoxon rank sum p > 1 × 10–3; Supplementary Fig. 6).
Coding RT burden and constraint. As expected for WES, the
vast majority (84.9%) of detected MEIs impacted the coding or
intronic sequence of a protein-coding gene or a regulatory ele-
ment targeted in the augmented WES assay described in Short
et al.15 (Fig. 2a). Due to the large numbers of individuals with
WES data in this study, we have ascertained over five-fold more
exonic variants than the largest previously published study
(Supplementary Fig. 7)4,5. Nonetheless, the number of MEIs
identified in this study, based on the proportion of the genome
assayed, likely represent only 2.2% of MEI variants genome wide
in these individuals.
Our large collection of coding variants allowed us to examine
the evolutionary forces acting on coding MEI variation (Fig. 2b).
To examine selective constraint, we utilized two common
measures: the proportion of variants observed in only one
individual (e.g., singletons)22 and the proportion of variants
found in genes likely to be intolerant of loss of function (LoF), as
determined by the pLI score23. To avoid issues of relatedness and
the potential for clinical ascertainment bias for pathogenic MEIs
in individual DD patients, only the 17,032 unaffected parents
sequenced as part of DDD were included in our analysis. MEIs
which directly impact exons are under strong selective constraint,
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Fig. 1 The DDD RT call set. a–e Histograms of the total number of variants per individual for the four classes of RT events identified in the DDD cohort (Alu:
blue; L1: green; SVA: orange; PPGs: red; combined RT events: grey) in size one bins. f Allele frequency distributions for the RT classes depicted in a–e in
log10 allele frequency bins. g Insert size estimates provided by MELT for the MEI classes ascertained in this study in log10 insert size bins. All plots only
include variants from unaffected parents
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indistinguishable from that of both nonsense and essential splice
site SNVs (Fig. 2b). Interestingly, we did not find any sign of
selection acting on intronic MEIs as they appear to be constrained
similarly to synonymous SNVs. In contrast to previous
studies24,25, we did not find a statistically significant (χ2 p <
0.05) bias toward intronic MEIs inserted in the antisense
orientation of the gene in which they are found (Supplementary
Fig. 8). This is likely not a repudiation of such work, but
attributable to the relatively small number of intronic events we
identified as part of our analysis compared with WGS4,24 or
reference genome-based25 studies. To put our findings on exonic
MEI constraint into perspective with other forms of variation,
every human genome will harbor approximately one (0.76 ± 0.62
SD per individual) MEI which directly impacts protein-coding
sequence. Since MEIs are similar to nonsense SNVs in terms of
deleteriousness (Fig. 2b), MEIs thus make up 0.6%22,26 of all
coding protein-truncating variants (PTVs; among SNVs, InDels,
and large CNVs) in each individual human genome.
While we were unable to perform similar population genetic
analyses for PPG events, due to the difficulty of resolving the
putative insertion site with WES data and thus distinguishing
between different PPGs for the same donor gene, we were able to
assess the propensity for specific genes to give rise to PPGs based
on their selective constraint. We observed that PPG donor genes
were significantly enriched for genes that are highly intolerant of
loss of function variation (pLI > 0.9). High pLI genes make up
25.3% of donor genes, compared with 17.6% of all protein-coding
genes (Fisher’s p= 2.6 × 10–4)22. This observation is likely driven
by loss-of-function intolerant genes being more likely to be highly
expressed in multiple tissues22, similar to genes known to have
been retroduplicated (Supplementary Fig. 6)19. This observation
implies that PPG events rarely strongly perturb the function of
their donor gene—despite several previously documented
instances of PPGs impacting expression or functionality of their
donor gene27.
Clinical annotation of de novo RT variants in DD. Using the
computational approaches outlined above, we identified a total of
11 germ-line de novo RT variants (Table 2). Our findings include
coding, noncoding, pathogenic, and benign variants, as well as, to
our knowledge, the first de novo MEI identified in a pair of
monozygotic twins (Supplementary Fig. 9). All de novo RT var-
iants were confirmed via a PCR assay specific to the RT class
(Fig. 3; Supplementary Fig. 9; Supplementary Fig. 12) and, where
possible, inspected for poly(A) tail and target site duplication—
hallmarks of bona fide RT activity28. We identified no de novo RT
variants which localized to the noncoding elements included on
the WES capture, which falls in line with expectations based on
mutation rate estimates (Fig. 4b). We also attempted to determine
the parental origin of each RT event using SNVs located on
sequencing reads which support the RT insertion (Table 2). Of
the 11 de novo RT events, we were able to phase three variants, all
to the father. While this finding is not statistically significant (χ2
p= 0.083), it fits with previous findings that the majority of de
novo structural variants9, and indeed most variant classes29, are
attributable to paternal origin.
Nine of our validated de novo mutations were MEIs (7 Alu and
2 L1), or a rate of approximately one de novo event per every
1000 patient exomes sequenced (9/9738). As expected, based on
both the total number of polymorphisms3–5 and mutation rate
(Table 1; Supplementary Table 3), we identified more Alu de novo
variants than the other RT classes. We also identified two PPG
germ-line de novo variants, or approximately one new PPG per
every 5000 patient WGS (2/9738). As a further quality control for
PPGs, we capillary sequenced all resulting PCR products to
confirm the gene of origin (Supplementary Fig. 12) and
performed WGS to identify the PPG insertion site. We were able
to localize the SERINC5 PPG to an ~50 Kbp intron of the gene
CLIC4 and the SLC35F2 event to an intergenic region between the
genes MAK and GCM2 (Fig. 3e). Neither of the events directly
impacted coding sequence and CLIC4 is neither under strong
selective constraint nor known to have any link with DD.
Each de novo mutation was then compared with known DD-
associated genes (using the Developmental Disorders Genotype-
to-Phenotype database–DDG2P) to identify potentially patho-
genic variants (Table 2). Of the mutations identified, four directly
inserted into coding exons of DD-associated and fetal brain-
expressed (see the Methods section; Supplementary Table 4)30
genes (Fig. 3, Table 2) with all four found in genes statistically
enriched for PTVs12 and therefore likely to operate by a LoF
mechanism. We did not identify any intronic de novo mutations
likely to be pathogenic (Fig. 3a–d; Supplementary Fig. 9). An
additional mutation inserted into the coding sequence of a
Alu
L1
SVA
0 250 500 750
Total sites
a
Non-
sense
Synonymous
Missense
Splice
Exonic Exonic
Intronic
Intronic
Alu
Combined MEIs
SNVs
0.5
0.6
0.7
0.8
0.1 0.2 0.3
Proportion of sites in high (>0.90) pLI genes
Pr
op
or
tio
n 
of
 s
in
gl
et
on
 s
ite
s
b
No
ne
UT
R
Int
ron
Ex
on
En
ha
nc
er
Fig. 2 Coding constraint on MEIs. a Cumulative consequence annotations
for Alu, L1, and SVA MEIs in all samples (n= 28,132 individuals) analyzed.
The majority of variants identified in this study fell within the noncoding
space (either an enhancer or intron). b Comparison of constraint between
MEIs and SNVs in unaffected parents. To compare the impact of exonic and
intronic Alu (blue) and all MEIs (grey) to varying classes of SNVs (black),
we used two metrics: the proportion of variants in genes that have been
identified as LoF intolerant as gauged by pLI-score22 (x-axis) and the
proportion of variants identified in only one individual (i.e., singletons; y-
axis). Error bars indicate 95% confidence intervals based on population
proportion; confidence intervals were calculated for SNVs, but are too small
to appear at the resolution displayed in this figure
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strongly LoF-intolerant gene, EZR (pLI= 0.99; Supplementary
Fig. 9), but we could not directly attribute it to the patient’s
phenotype due to lack of significant enrichment for PTVs,
although there is prior evidence for a role in a familial DD
syndrome31. The four mutations in DD-associated genes were
reported to the referring clinician for clinical interpretation based
on both initially reported and updated phenotypes (Supplemen-
tary Table 2). Three out of four reported mutations (NSD1,
MEF2C, and ARID2) were subsequently deemed to be likely
causative of the patient’s phenotype (Supplementary Table 2) by
the referring clinician. To determine if our patient with a likely
pathogenic NSD1 variant phenocopies the already described
aberrant blood DNA methylation signature typical of Sotos
syndrome patients32, we compared our patient’s genome-wide
methylation status to several already published Sotos syndrome
cases (see the Methods section)32. Our patient strongly clusters
with other confirmed Sotos syndrome patients and confirms our
clinical assessment and diagnosis of this particular patient
(Supplementary Fig. 10). The fourth patient, with an Alu
insertion in SETD5 (Fig. 3a), has clinical features (polydactyly
and truncal obesity; Supplementary Table 2) more suggestive of a
ciliopathy. As such, the identified MEI is unlikely to be the sole
cause for the patient’s DD, but may contribute to a composite
phenotype. Accordingly, we did investigate this patient’s exome
for other potentially diagnostic variants, but did not identify
additional de novo or inherited variation that could plausibly be
associated with this patient’s phenotype.
We also examined our data set for inherited rare pathogenic
RT variants. We evaluated variants inherited from an affected
parent, bi-allelic inheritance (either a homozygous MEI or a
heterozygous MEI paired with another variant class), and X-
linked variants maternally inherited by affected males. We did
neither identify any rare MEI variants inherited from an affected
parent nor any compound heterozygous individuals with a rare
MEI and a non-MEI PTV (e.g., SNV/InDel) impacting the same
gene. We did identify a single proband-specific homozygous MEI
inserted into an exon of PAN2 which was unique to a single
family. This gene was recently identified as nominally significant
(genome wide p= 4.2 × 10–4) in a study investigating the role of
recessive variants in DD13, although more data are required to be
confident of its association to DD. We also identified a total of 22
(14 Alu, 7 L1, and 1 SVA) polymorphic MEIs on the X
chromosome, of which 4 (3 Alu and 1 L1) directly impacted
protein-coding sequence. Of these variants, none were at a low
enough allele frequency to be reasonably DD associated, were
located within a gene associated with DD, nor fit an inheritance
pattern consistent with X-linked disease.
Mutation rate and enrichment of deleterious RT events in
DDD. Based on our findings, in the coding and peri-coding
portion of the genome, one out of every 2434 DD cases (0.04% ±
0.04; 95% CI) is directly attributable to RT-derived mutagenesis.
To determine both if our observed number of de novo variants
meets expectation and if our patient cohort is enriched for causal
de novo RT events, we estimated the population mutation para-
meter, Θ33, from the unaffected parents in the DDD study and
from the 1KGP4,5 (Supplementary Table 3). The resulting cal-
culation gives very similar estimates of MEI mutation rate
(combined across Alu, L1, SVA) of between 1.4 × 10–11 (1KGP)
and 1.2 × 10–11 (DDD) variants per bp per generation (μ), or ~1
new MEI genome-wide per every 12–14 births—largely con-
cordant with prior estimates from WGS data sets3,34,35.
Using this genome-wide mutation rate, we estimated the
number of expected mutations in various genomic compart-
ments, including within genes intolerant to PTVs and withinT
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DD-associated genes (Fig. 4; Methods). We identified a significant
enrichment of de novo MEIs in dominant DD-associated genes
(Poisson p= 2.86 × 10–5), but not in the much larger set of LoF
intolerant genes (Poisson p= 0.05). To ensure that this finding
was not due to inaccurate estimation of the genome-wide
mutation rate, we also assessed the probability that four out of
six exonic de novo MEIs would fall within exons of dominant
DD-associated genes by chance, based on the proportion of the
exome represented by these genes (and assuming known DD-
associated genes have the same MEI mutation rate as other genes)
and likewise found a significant enrichment (p= 4.3 × 10–5; see
the Methods section).
Discussion
Here, we have described the development, validation, and
exemplification at scale of an analytical pipeline for the rapid
assessment of patient genomes for RT variants. We have used
these approaches to present the largest study examining the
coding genome for RT-derived variation to date (Table 1; Fig. 1).
With this data set, we first demonstrated that exonic MEIs
(regardless of insertion length) are under selective constraint on
par with protein-truncating SNVs (Fig. 2). We identified four
likely pathogenic RT mutations, two Alu and two L1 insertions
(Fig. 3), all of which arose de novo in known haploinsufficient
DD-associated genes (Fig. 3a–d), implying that dominant loss-of-
function is the major mode of pathogenic exonic RT variation.
Finally, we estimated the genome-wide MEI mutation rate and
used it to determine that DDD probands are enriched for
damaging RT variation within exons of dominant DD-associated
genes (Fig. 4a).
The total number of polymorphic, exonic RT variants identi-
fied in DDD is concordant with previous studies characterizing
MEI variation3,5,36. Pathogenic MEIs make up 0.04% of diagnoses
in the DDD study (4/9,738 probands), a small yet individually
significant collection of diagnostic variants. We additionally
investigated our data for causative, inherited MEIs, and did not
identify any such events. We infer that despite making up a
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significant proportion of reported MEI variants in the clinical
literature7, bi-allelic or X-linked MEI events are a less frequent
class of pathogenic variant in developmental disorders. This is in
keeping with recent estimates13 that in a largely outbred clinical
population, such as in the UK, recessive disorders caused by
coding variants account for a much smaller fraction of patients
than dominant disorders. We also attempted to investigate both
the parental origin of de novo variants (Table 2) and the
mosaicism of MEIs with low variant allele frequency (Supple-
mentary Fig. 2). In both cases, additional work incorporating
long-read technology is needed to ascertain parental contribution
and, in the case of parental mosaic MEIs, potential
recurrence risk.
Interestingly, it appears that the contribution of diagnostic RT
variants may vary among diseases. Wimmer et al.37 reported a
total of 13 diagnostic, exonic MEI variants in 4500 neurofi-
bromatosis type I patients (0.3% of patients). This rate is seven
times higher than that observed in DDD, and was attributed to a
potential RT mutation hotspot associated with the canonical L1
endonuclease cleavage site of 3′-AA/TTTT-5′38 within the
neurofibromatosis-associated gene, NF1. A recent study using a
cell culture retrotransposition assay to study MEI site preference
was unable to identify a mutation hotspot in NF139, and therefore
suggests further work is needed to investigate the role of sequence
context in determining the overall genomic landscape of RT-
mediated disease. Analogously, inclusion of sequence context into
the SNV mutation model noticeably improved the ability to
determine enrichment/depletion of deleterious SNVs within
genes22,23.
Our study is limited in that by analyzing exome sequences we
only identified ~2% of the RT variants in each individual human
genome studied4,5. Despite a number of known disease-associated
intronic MEIs in the literature, we did not identify a pathogenic
intronic MEI. As such, it remains an open question as to what
contribution RT mutations in the noncoding genome play in the
etiology of DD. While it appears that the contribution of reg-
ulatory elements to DD is relatively small, as defined by this
(Fig. 4b) and other studies15, previous work has identified a
significant signature of purifying selection against MEI events
within 100 bps of exons25—variants which our study could
potentially identify. As our data suggest that the majority of DD
cases with pathogenic coding MEIs are due to de novo insertions
(Table 2; Fig. 3), we conjecture that most additional DD-
associated MEIs may be located in the introns of known DD-
causing genes and disrupt splicing—a known disease mechanism
attributable to RT-derived mutagenesis7,37,40. Simulations suggest
that under a null genome-wide mutation model, we should expect
to observe 12.3 (5.4–19.2, 95% CI) de novo intronic RT mutations
in dominant DD-associated genes in a population sample of 9738
individuals. As such, a WGS study of a clinical population of
similar size to that analyzed here should be well powered to
estimate the pathogenic contribution of intronic MEIs.
De novo MEIs are typically readily interpretable with modest
informatics expertise, and represent a clinically relevant class of
variation to assay in clinical bioinformatics pipelines. While we
ultimately find that the overall burden of RT-attributable disease
is relatively low in the human population, it is nonetheless an
important consideration when elucidating the genetic basis of
disease in individual patients.
Methods
Patient recruitment and sequencing. A total of 13,462 patients were recruited
from 24 clinical genetics centers from throughout the UK and the Republic of
Ireland as previously described41. Informed consent was obtained for all families,
and the study was approved by the UK Research Ethics Committee (see the
Acknowledgements section). For the purposes of this study, individuals that were
not recruited as part of a trio (e.g., individual patients or patients with just one
parent), were included on the DDD sample blacklist, or failed to meet MELT QC
requirements5 were excluded from downstream analysis (leaving n= 9738 pro-
bands; 28,132 individuals). Sequencing of families and alignment to build GRCh37
of the human reference genome with bwa42 were performed as previously
described12.
Processed pseudogene pipeline development. PPGs, particularly young poly-
morphic events, share highly homologous sequence with the source gene from
which they are derived. Consequently, the WES bait capture method will capture
both DNA from the original donor gene and the new daughter copy. This allows,
compared with our approach for MEI discovery, for ascertainment of PPGs gen-
ome wide. While this approach does come with limitations, such as difficulty in
identifying insertion variants, we can still determine events per individual.
Our discovery pipeline functions in two steps: first we collect read evidence on
an individual level to determine which genes have been retroduplicated in that
individual (Supplementary Fig. 1). Second, we determine presence/absence of each
PPG in every individual in the DDD cohort based on the gene models built in the
first step. In step one, we iterate over all genes in the ENSEMBL gene database
which have a determined pLI score22 and collect discordant read pairs (DRPs)
which map between exons and have an insert size > 99.5% of all other reads in the
sample. If more than four reads linking two exons are found, the gene is considered
to be retroduplicated elsewhere in the genome. In step two, for each gene identified
in step one, all evidence across all PPG-positive individuals are pooled to make a
model of the PPG. This model is then used to check for DRP and split read pair
(SRP) evidence in all genomes. If an individual has at least five total read pairs of
supporting evidence with at least one SRP and one DRP, an individual is
considered positive for the given PPG. All genes and individuals were combined
into a flat file listing presence or absence of a given PPG in each individual.
MEI call set generation and consequence annotation. To identify MEIs in the
DDD WES data, we utilized the previously published MELT5. MELT was run with
default parameters (except the “-exome” flag during IndivAnalysis) using “Split”
mode to generate a final unified VCF-format file43 of all 28,132 unfiltered indivi-
duals independently for each MEI type (Alu, L1, SVA). Following initial data set
generation, we found that a subset of variants internal or adjacent to (±50 bp) low
complexity repeats (defined here as a run of sequence ≥15 bp composed of two or
fewer nucleotides) were likely false positive. As such, we added an additional filter
to the final MELT VCF, lc (low complexity), which removes such false positives
from downstream analysis. Variants that could not be genotyped in at least 25% of
individuals, had ≤ 2 split reads, had MELT ASSESS score < 3, or had any value in
the VCF FILTER column other than PASS or rSD were filtered.
To determine if variants per individual approximated a Poisson distribution, we
calculated the mean number of sites per unrelated individual (λ) independently for
each RT class and for all RT classes combined as displayed in Fig. 1a–e. Our
calculated λ was then supplied to the function rpois in R to generate a random
deviate and plotted alongside histograms identical to Fig. 1a–e in Supplementary
Fig. 3.
To generate consequences plotted in Fig. 2a, all MEIs were annotated using
Variant Effect Predictor v88 (VEP)44 on human genome build GRCh37 and
intersected with bedtools intersect45 to enhancers (one of heart46, VISTA47, or
highly evolutionarily conserved48) included on the DDD WES capture15. Only a
single consequence was retained for each variant, with priority given to enhancer
annotation. Primary transcript as determined by VEP was used for all gene-based
consequences, pLI score22 annotation, and DDG2P disease association (Table 2).
Assessment of potentially mosaic MEIs. To determine the mosaicism of variants
that were identified as false-negative de novo during initial MELT analysis (i.e.,
genotyped as heterozygous in a single proband and homozygous reference in both
parents), we randomly selected 1000 trios and determined the total number of
reads supporting both the insertion and reference allele (i.e., allelic proportion) at
all 917 Alu loci identified in this study. Alongside this data, we plotted the parental
allelic proportion at the 15 false-negative Alu loci described above (Supplementary
Fig. 2a). To formalize this result and ensure that these specific loci do not have
higher genotyping or sequencing error than other loci, we performed three ana-
lyses. First, we compared the combined allelic proportion of all heterozygous
variants to the combined allelic proportion of both false-negative parents and the
associated heterozygous probands (Supplementary Fig. 2b). Second, we examined
the allelic proportion for all homozygous reference genotypes at each false-negative
locus for evidence of higher error rates based on higher average allelic proportion at
those loci using a z-test (Supplementary Fig. 2c). Finally, to assess if these loci had
similar read start distributions in both parent and proband, we retrieved all read
start sites within 250 bps of each insert site and used a Kolmogorov–Smirnov test to
compare the two distributions. Only one locus, chr11:g.95523918_95523919insAlu
(1_280), showed a significant difference at a threshold of p= 0.05 (K.S. test p=
2.70 × 10–4).
Since these sites are not likely to be genotyping or sequencing artifact, we next
attempted to clarify the nature of a subset of variants with a custom long-range
PCR and Pacific Biosciences sequencing approach. The goal of this methodology
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was to attempt to both validate and phase candidate mosaic MEIs to nearby (±5
Kbps) SNVs. As above, we limited our analysis to Alu MEIs as the large insert
length of L1 (n= 1) and repeat heavy SVA (n= 2) elements would likely prove
refractory to long PCR with enough flanking sequence to phase to nearby SNVs. To
design locus specific primers, the genomic region surrounding each target MEI was
entered into Primer-BLAST [www.ncbi.nlm.nih.gov/tools/primer-blast/] using
default parameters. Each locus was targeted with three primer pairs: one pair
amplifying a 10 kb region with the MEI lying centrally, and two pairs of primers to
amplify 5 kb fragments extending up and downstream of the MEI. In total, 10 kb
PCRs were performed using AccuTaq LA DNA Polymerase (D8045, Sigma-
Aldrich) with the following parameters: 98° denaturation for 1 min, followed by 30
cycles of 94° (30 s)/54° (30 s)/68 degrees (11 min), with a final extension of 18 min
at 68°. Total 5 kb PCRs were performed as above, but with a reduced 6 min
extension time at 68°s, and a final extension time of 10 min. After quality checking
the PCRs on control DNA, 100–200 ng of both parental and proband DNA were
amplified in a 50 µl PCR reaction using the same parameters.
After confirming amplification by agarose gel, PCR products were isolated using
SPRI bead purification (Ampure-XP, Agilent), quantified, and mixed in equimolar
amounts. We then performed a standard PacBio library prep using SMRTbell
Template Prep Kit 1.0 (part no. 100-991-900) without size selection. Sequencing
was performed on the Pacific Biosciences Sequel platform using Sequel Sequencing
Kit 3.0 (101-597-800) and Sequel SMRT cell 1 M v3 (101-531-000). For error
correction, raw sequencing reads were then provided as input to pbccs v3.4.1
[https://github.com/PacificBiosciences/unanimity] with default parameters other
than minLength= 100. Corrected reads were then aligned to the human genome
using blasr v5.3.349 and downsampled to between 2000–3000× coverage per locus
assessed.
MEIs were then phased to the nearest heterozygous SNV on a per-read basis
using a custom java pipeline. After dropping sites due to PCR errors or phasing
ambiguity, we were able to examine a total of 6 Alu MEIs (Supplementary Data 2).
The total number of reads supporting each of four possible phases (MEI+ SNV+ ,
MEI+ SNV−, MEI-SNV+ , MEI-SNV−) were then quantified. Primers and
quantification of the results are available in Supplementary Data 2.
Quality control of RT data using WGS and 1KGP. To determine if our MEI WES
call set was biased compared with WGS data, we performed two independent
comparisons: (1) to high coverage (>30 ×) WGS data generated for a subset of
DDD trios; and (2) to a published collection of MEIs from 1KGP phase III5.
For WGS quality control, we used a subset of 30 DDD trios (n= 90
individuals), which were previously whole-genome sequenced. MEI discovery using
MELT5 on all 90 individuals was performed and filtered identically to the WES
data. Genotypes identified in the WGS data but not in WES were then separated
based on coverage in the corresponding WES. Genotypes in low coverage areas (<
10 ×) were considered not possible (n.p), while variants where coverage was greater
than 10x are considered not detected (n.d). All remaining genotypes were than
compared for identity between the WGS and WES results (Supplementary Table 1).
To compare the DDD MEI call set to the 1KGP, we first filtered 1KGP calls to
variants with mean > 10× coverage in 1000 randomly sampled DDD WES
individuals (leaving 318 Alu, 81 L1, and 26 SVA). We then randomly selected 2453
DDD parents 1000 times, retaining only loci present in downsampled
individuals4,5. The resulting distribution was then compared with the observed
number of variants in the 1KGP-masked data to generate z-scores independently
for all three MEI types (Supplementary Fig. 4).
To compare our PPG data set to Zhang et al.6, we downloaded provided
Supplementary tables. We then summed the total number of unique events per
person, and determined counts for each gene reported. Genes were then matched
between our call set and Zhang et al.6 using ENSEMBL gene identifiers, and allele
counts between each data set were plotted to create Supplementary Fig. 5.
GTEx annotation of processed pseudogenes. To determine RNA expression
levels of donor genes which gave rise to PPGs identified in this study, we queried
transcript per kilobase per megabase of sequencing (TPM) scores for all genes in 30
tissues assessed by the current GTEx v7 release [https://gtexportal.org/home/
datasets]. Only the 18,225 protein-coding genes which were assessed for gene PPGs
by our project were retained for subsequent analysis. TPM values were then
averaged across all GTEx individuals for a given tissue to generate a mean TPM
value as plotted in Supplementary Fig. 6. Nonparametric Wilcoxon rank-sum tests
were performed using the wilcox.test function in R with default parameters to
generate p-values for both within tissue and between tissue comparisons.
SNV calling and quality control. To call SNVs from all DDD individuals, we
utilized GATK 3.5-0-ge91472d50 in three steps using default settings. First, we
called variants in individual samples using HaplotypeCaller. Next, individual VCF
files were processed in 200 individual batches using CombineGVCFs. Finally, all
batched VCFs were passed to GenotypeGVCF to generate a final joint-called VCF
file. This file was then annotated using VEP v8844 on build GRCh37 of the human
genome; final annotations were determined only for the canonical transcript as
determined by VEP. Unaffected parents (n= 17,032 individuals) were then
extracted from this VCF and only variants with an allele count ≥ 1 in these indi-
viduals were retained.
For initial filtering, we removed SNVs with a VQSLOD <−2.0, read depth < 8,
and genotype quality < 20. We next performed more extensive QC using a
“missingness” score identical to the method described in Martin et al.13. In short,
each genotype at a given variant was assessed for genotype quality (GQ), depth
(DP), and a binomial test for allelic depth (i.e., number of alternate vs. reference
supporting reads; AD). If a given genotype had GQ < 20, DP < 8, or AD p-value <
0.001, it was considered “missing”. If more than 50% of genotypes for a given
variant were missing, the variant was subsequently filtered from final analysis.
Allele frequencies were recalculated based on included individuals while
accounting for missing genotypes.
Selective constraint of SNVs and MEIs. As sensitivity of variant discovery can
bias our results, we generated an accessibility mask of the DDD WES data where
we expect our variant ascertainment sensitivity to be > 95% (Supplementary
Fig. 11)5. Our mask thus includes only regions of the genome that contain at least
10× average coverage in a mean cohort of 1000 randomly selected individuals for a
total of 74.2 Mbp, or ~2.3% of the genome (Supplementary Table 3). Using this
mask, we filtered our original 1129 variants down to 790 (653 Alu, 107 L1, and 30
SVA) variants in unaffected parents (n= 17,032 individuals). Parents were deter-
mined to be affected either by the referring clinician or, where ambiguous, through
manual curation of HPO terms for a matching parent–offspring phenotype.
Using this masked subset of variants, we determined genomic constraint as
shown in Fig. 2b. Allele frequency values were recalculated for all variants, and a
pLI score22 for each MEI was added as described above. MEIs which did not insert
into a gene or inserted into a gene without a calculated pLI score22 were excluded
from subsequent analysis. We then calculated proportion of singleton variants and
proportion of variants in high pLI genes independently for Alu and, due to low
overall numbers of the other MEI subtypes, for a combined set of Alu, L1, and
SVA. SNVs annotated as nonsense, missense, synonymous, or splice acceptor/
donor (splice in Fig. 2b) as determined by VEP v8844 were extracted from the SNV
VCF files described above and used to calculate singleton and pLI proportion
identically to MEIs.
Fetal brain expression data. To assess if genes disrupted by RT variants were
expressed in the fetal brain, we downloaded per-gene expression data generated by
the BrainSpan consortium (file: genes_matrix_csv.zip [http://www.brainspan.org/
static/download.html])30. From this file, we extracted columns representing data
generated from fetuses 15 to 37 weeks post conception. These data were then
provided as input to a custom python script which calculated the median RPKM of
all genes provided for the file. Genes with a median RPKM ≥ 1 were considered
expressed in the fetal brain (n= 15,474). Likely causal RT variants (n= 4) were
then intersected with this list to determine gene expression status. As RPKM ≥ 1 is
a rather liberal cutoff, we also ranked these genes compared with other genes in our
expression list; these values are reported in Supplementary Table 4.
MEI validation by PCR. To validate all nine de novo MEI variants (Table 2) and
the homozygous insertion in PAN2, we used the following PCR protocol: primers
were designed using Primer351 to make products spanning the predicted insertion
site (Supplementary Data 1). PCR was carried out using Platinum™ Taq DNA
Polymerase High Fidelity (Invitrogen); 20 ng of genomic DNA extracted from
blood or saliva was amplified in the presence of 0.2 μM of each primer and 1 unit of
Platinum™ Taq. Amplification was carried out using the following cycling condi-
tions; for Alu insertions: 2 min at 94 °C, followed by 36 cycles of (30 s at 94 °C, 30 s
at 60 °C, and 1 min at 68 °C); for LINE1 insertions: 2 min at 94 °C, followed by 36
cycles of (30 s at 94 °C, 30 s at 60 °C, and 7 min at 68 °C). PCR products were
visualized using a 2% agarose E-Gel® (Invitrogen).
Processed pseudogene validation. To validate the two de novo PPG variants
(Table 2), we used the following PCR protocol: primers were designed using Pri-
mer351 to make products within the exons of each gene. Forward and reverse
primers were then paired between exons to amplify across the excised intronic
regions (Supplementary Data 1). PCR was carried out using either Platinum™ Taq
DNA Polymerase High Fidelity (Invitrogen) or Thermo-Start Taq DNA Poly-
merase (Thermo Scientific). Platinum™ Taq assay: 20 ng of genomic DNA extracted
from blood or saliva was amplified in the presence of 0.2 μM of each primer, and 1
unit of Platinum™ Taq. Amplification was carried out using the following cycling
conditions; 2 min at 94 °C, followed by 36 cycles of (30 s at 94 °C, 30 s at 60 °C, and
1 min at 68 °C). Thermo-Start Taq DNA Polymerase assay: 40 ng genomic DNA
was amplified in the presence of 0.2 μM of each primer and 0.42 units of Thermo-
Start Taq. Cycling conditions were as follows: 5 min at 95 °C, six cycles of (30 s at
95 °C, 30 s at 64 °C, and 1 min at 72 °C), six cycles of (30 s at 95 °C, 30 s at 62 °C,
and 1 min at 72 °C), six cycles of (30 s at 95 °C, 30 s at 60 °C, and 1 min at 72 °C)
followed by 36 cycles of (30 s at 95 °C, 30 s at 58 °C, and 1 min at 72 °C) with a final
elongation of 10 min at 72 °C. PCR products were visualized using a 2% agarose E-
Gel® (Invitrogen). PCR products were sequenced using either the forward or
reverse primer used in the amplification protocol by Eurofins GATC Biotech
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GmbH. Sequence traces were aligned using SeqMan Pro 15 (Lasergene 15) and
reads were aligned to the human genome (build GRCh37) using BLAT52.
WGS of probands with de novo processed pseudogenes. To validate and
determine the insertion site of the two identified de novo PPGs (Table 2), we
performed Illumina WGS on all individuals of each trio in which the de novo
event was identified (n= 6 individuals). Samples were first quantified with
Biotium Accuclear Ultra high sensitivity dsDNA Quantitative kit using Mos-
quito LV liquid platform, Bravo WS and BMG FLUOstar Omega plate reader
and cherrypicked to 500 ng/120 μl using Tecan liquid handling platform.
Cherrypicked plates are then sheared to 450 bp using a Covaris LE220 instru-
ment and subsequently purified using SPRI Select beads on Agilent Bravo WS.
Library construction (ER, A-tailing and ligation) was performed using “NEB
Ultra II custom kit” on an Agilent Bravo WS automation system. Samples were
then tagged using NextFLEX Unique Dual Indexed adapter 1–96 barcodes at the
ligation stage. Libraries were then quantified by qPCR using Kapa Illumina ABI
Sanger custom qPCR kits using a Mosquito LV liquid handling platform, Bravo
WS, and Roche Lightcycler. Libraries are then pooled in equimolar amounts on a
Beckman BioMek NX-8 liquid handling platform and normalized to 2.4 nM for
cluster generation on a c-BOT and then sequenced on the Illumina TenX
sequencing platform. Following sequencing, reads were aligned with BWA
mem42 (with settings -t 16 -p -Y -K 100000000) to build GRCh37 of the human
reference genome. Reads were then manually inspected using the Integrative
Genomics Viewer (IGV)53 to confirm presence, de novo status, and parent of
origin of each PPG.
Methylation analysis. Methylation analyses were performed in accordance with
the methods detailed in Choufani et al.32. In short, we downloaded publicly
available methylation data from GEO (accession GSE74432) generated by Choufani
et al.32 and combined it with Illumina EPIC methylation array data generated in-
house for our Alu NSD1 loss-of-function patient (Fig. 3b; Table 2). Following data
curation, we randomly sampled a subset of 15 cases (defined by Choufani et al.32 as
a carrier of an NSD1 loss of function variant) and 15 controls to identify a set of
differentially methylated signature CpGs based on a 20% effect size cutoff and 0.01
FDR-corrected p-value which separated case and control individuals. Once a sig-
nature was established, we used Pearson correlation to assess each sample’s simi-
larity to a mean case and mean control based on differential methylation at
signature CpG sites. Confirmed pathogenic NSD1 variants and control samples
used to build the signature were not included in the correlation analysis (Sup-
plementary Fig. 10).
MEI mutation rate and burden. To determine the mutation rate independently for
each MEI type (Alu, L1, SVA), we utilized data generated by both DDD and the
1KGP5. For DDD data, we filtered sites as above based on our > 10× coverage
accessibility mask. For the 1KGP data5, we created a combined mask from three
different data sources: (1) the pilot accessibility mask generated by the 1KGP
project phase III54, which removes regions of the genome inaccessible to variant
calling, (2) reference ME sequences as identified by repeatmasker55, as MELT is
unable to accurately ascertain MEIs in these regions, and (3) All sequence ± 10 Kbp
from the 5′ and 3′ terminus of all protein-coding genes from RefSeq56. This mask
was generated separately for Alu and L1 and did not filter 1113.0 Mbp or 959.9
Mbp of the genome, respectively. The Alu mask was used for filtering SVA and
both masks excluded both allosomes. On masking the 1KGP data, we were left with
a total of 10,930 autosomal MEIs (8,554 Alu, 2,047 L1, 329 SVA). Following
filtering of the DDD and 1KGP sets with their corresponding masks, we used the
Watterson estimator with an effective population size of 10,000 for all calculations
to estimate the population mutation parameter, Θ33, and mutation rate, μ (Sup-
plementary Table 3).
We next used our estimate of μ to determine the expected number of de novo
MEI mutations in exons, enhancers, and introns genome-wide. To calculate this
value, we extrapolated μ for 9738 births (i.e., number of probands in our study),
resulting in an estimate of 677 de novo MEIs genome wide. We then simulated this
number of variants 100 times genome-wide using bedtools random45 and
annotated the resulting simulated variants identically to real variants reported in
this study (e.g., as in Fig. 2a). The total number of expected variants in the three
categories depicted in Fig. 4 were then averaged across all simulations to determine
Poisson λ of de novo variants under neutral mutation rate. These distributions were
then statistically compared with the number of observed variants in DDD using the
ppois function in R (Fig. 4).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequencing, phenotype data, and variant calls for all data in this paper are accessible via
the European Genome-phenome Archive (EGA) under study number
EGAS00001000775 [https://www.ebi.ac.uk/ega/studies/EGAS00001000775]. Within this
study, WES files of all DDD families are provided as part of data set EGAD00001004390,
and RT variant calls and WGS data of the two individuals with de novo PPG variants are
provided as part of data set EGAD00001004586.
Code availability
We have deposited R code, source data files, and raw blots from PCRs used to generate
main text and Supplementary figs. online at the following github repository [https://
github.com/eugenegardner/MEIPaper.git]. Source code and more information for the
PPG discovery pipeline used in this paper is available online at github [https://github.
com/eugenegardner/Retrogene.git].
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